4,5-二氯-6-甲基-2-(2-吡啶基)嘧啶 | 306935-55-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4,5-二氯-6-甲基-2-(2-吡啶基)嘧啶
• 英文名称: 4,5-dichloro-6-methyl-2-(pyridin-2-yl)pyrimidine
• 英文别名: 4,5-dichloro-6-methyl-2-pyridin-2-yl-pyrimidine；4,5-dichloro-6-methyl-2-pyridin-2-ylpyrimidine
• CAS: 306935-55-7
• 化学式: C₁₀H₇Cl₂N₃
• mdl: MFCD00097945
• 分子量: 240.092
• InChiKey: VJJVPBQJWNMJFC-UHFFFAOYSA-N

物化性质

• 熔点：
  132-133°C
• 沸点：
  270.4±22.0 °C(Predicted)
• 密度：
  1.375±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39,S45
• 危险类别码：
  R36/37/38,R25

SDS

Name:	4 5-Dichloro-6-methyl-2-(2-pyridyl)pyrimidine 97% Material Safety Data Sheet
Synonym:
CAS:	306935-55-7

Section 1 - Chemical Product MSDS Name:4 5-Dichloro-6-methyl-2-(2-pyridyl)pyrimidine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
306935-55-7	4,5-Dichloro-6-methyl-2-(2-pyridyl)pyr	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 306935-55-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 132 - 133 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H7Cl2N3
Molecular Weight: 240

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 306935-55-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4,5-Dichloro-6-methyl-2-(2-pyridyl)pyrimidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 306935-55-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 306935-55-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 306935-55-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	5-chloro-6-methyl-2-(pyridin-2-yl)pyrimidin-4-ol	286430-67-9	C10H8ClN3O	221.646

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	5-Chloro-6-methyl-2-pyridin-2-ylpyrimidin-4-amine	256370-28-2	C10H9ClN4	220.661
  ——	5-chloro-N,N,6-trimethyl-2-pyridin-2-ylpyrimidin-4-amine	289706-51-0	C12H13ClN4	248.715
  ——	5-chloro-N,N-diethyl-6-methyl-2-pyridin-2-ylpyrimidin-4-amine	1121728-18-4	C14H17ClN4	276.769
  ——	5-chloro-N-(2-cyclohexylethyl)-6-methyl-2-pyridin-2-ylpyrimidin-4-amine	1121728-28-6	C18H23ClN4	330.86
  ——	5-chloro-6-methyl-N-(3-phenylpropyl)-2-pyridin-2-ylpyrimidin-4-amine	1121728-23-1	C19H19ClN4	338.84
  ——	N-benzyl-5-chloro-6-methyl-2-pyridin-2-ylpyrimidin-4-amine	256370-27-1	C17H15ClN4	310.786
  ——	5-chloro-6-methyl-2-pyridin-2-yl-N-(2-pyridin-4-ylethyl)pyrimidin-4-amine	1121728-47-9	C17H16ClN5	325.801
  ——	5-chloro-N-(cyclohexylmethyl)-6-methyl-2-pyridin-2-ylpyrimidin-4-amine	1121728-26-4	C17H21ClN4	316.834
  ——	5-chloro-N-[2-(4-chlorophenyl)ethyl]-6-methyl-2-pyridin-2-ylpyrimidin-4-amine	1121728-43-5	C18H16Cl2N4	359.258

反应信息

• 作为反应物：
  描述：

  4,5-二氯-6-甲基-2-(2-吡啶基)嘧啶 在 氨 、 三乙胺 作用下， 以 乙醇 为溶剂， 生成 5-Chloro-6-methyl-2-pyridin-2-ylpyrimidin-4-amine
  参考文献：
  名称：

  具有体外抗血浆和抗疟疾活性的2-吡啶基嘧啶的合成和评价

  摘要：

  合成了一系列2-吡啶基嘧啶，已报道恶性疟原虫蛋氨酸氨基肽酶1b的抑制剂，并评估了它们的抗血浆活性。理化性质的分析表明亲脂性和抗寄生虫活性之间的联系。针对培养的利什曼原虫donovani寄生虫的文库的交叉筛选揭示了这类化合物是体外寄生虫发展的有效抑制剂。

  DOI：

  10.1016/j.bmcl.2008.11.098
• 作为产物：
  描述：

  5-chloro-6-methyl-2-(pyridin-2-yl)pyrimidin-4-ol 在 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 以67 %的产率得到4,5-二氯-6-甲基-2-(2-吡啶基)嘧啶
  参考文献：
  名称：

  抑制隐球菌生长的四唑衍生物的筛选与合成

  摘要：

  化合物8-氟-7-甲基-5-(吡啶-2-基)四唑并[1,5-c]嘧啶和5-(吡啶-2-基)-8,9-二氢-7H-环戊基[e ]四唑并[1,5-c]嘧啶属于一类新型抗真菌药。两种具有四唑骨架的化合物均表现出与传统药物相同或优于传统药物的抑制活性（按重量/体积计算），对每种隐球菌属物种的 IC 50等于 0.05 μM (0.012 μg mL -1 ) 。因此，含四唑主链的化合物可能是具有独特抗隐球菌病机制的新型抗真菌药物。抗真菌药物念珠菌隐球菌高通量筛选四唑

  DOI：

  10.1002/cmdc.202300157

文献信息

• Novel Pyrimidine- And Triazine-Hepcidine Antagonists
  申请人：Dürrenberger Franz

  公开号：US20120202806A1

  公开（公告）日：2012-08-09

  The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

  本发明涉及新的肝铁蛋白拮抗剂，包含它们的药物组合物以及将其用作药物的用途，特别是用于治疗铁代谢紊乱，如特别是铁缺乏病和贫血，特别是与慢性炎症性疾病相关的贫血（ACD：慢性疾病性贫血和AI：炎症性贫血）。
• [EN] INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS<br/>[FR] INHIBITEURS DE LA MÉTHIONINE AMINOPEPTIDASE HUMAINE 1 ET PROCÉDÉS DE TRAITEMENT DE TROUBLES
  申请人：LIU JUN O

  公开号：WO2009064388A3

  公开（公告）日：2009-08-27
• Pyridinylpyrimidines selectively inhibit human methionine aminopeptidase-1
  作者：Pengtao Zhang、Xinye Yang、Feiran Zhang、Sandra B. Gabelli、Renxiao Wang、Yihua Zhang、Shridhar Bhat、Xiaochun Chen、Manuel Furlani、L. Mario Amzel、Jun O. Liu、Dawei Ma

  DOI：10.1016/j.bmc.2013.02.023

  日期：2013.5

  Cellular protein synthesis is initiated with methionine in eukaryotes with few exceptions. Methionine aminopeptidases (MetAPs) which catalyze the process of N-terminal methionine excision are essential for all organisms. In mammals, type 2 MetAP (MetAP2) is known to be important for angiogenesis, while type 1 MetAP (MetAP1) has been shown to play a pivotal role in cell proliferation. Our previous high-throughput screening of a commercial compound library uncovered a novel class of inhibitors for both human MetAP1 (HsMetAP1) and human MetAP2 (HsMetAP2). This class of inhibitors contains a pyridinylpyrimidine core. To understand the structure-activity relationship (SAR) and to search for analogues of 2 with greater potency and higher HsMetAP1-selectivity, a total of 58 analogues were acquired through either commercial source or by in-house synthesis and their inhibitory activities against HsMetAP1 and HsMetAP2 were determined. Through this systematic medicinal chemistry analysis, we have identified (1) 5-chloro-6-methyl-2-pyridin-2-ylpyrimidine as the minimum element for the inhibition of HsMetAP1; (2) 5'-chloro as the favored substituent on the pyridine ring for the enhanced potency against HsMetAP1; and (3) long C4 side chains as the essentials for higher HsMetAP1-selectivity. At the end of our SAR campaign, 25b, 25c, 26d and 30a-30c are among the most selective and potent inhibitors of purified HsMetAP1 reported to date. In addition, we also performed crystallographic analysis of one representative inhibitor (26d) in complex with N-terminally truncated HsMetAP1. (C) 2013 Elsevier Ltd. All rights reserved.
• PYRIMIDINE ALS HEPCIDIN-ANTAGONISTEN
  申请人：VIFOR (INTERNATIONAL) AG

  公开号：EP2473486B1

  公开（公告）日：2015-10-28
• NEUE PYRIMIDIN- UND TRIAZIN-HEPCIDIN-ANTAGONISTEN
  申请人：VIFOR (INTERNATIONAL) AG

  公开号：EP2473486A1

  公开（公告）日：2012-07-11